Proactive London's Andrew Scott sat down with Verona Pharma PLC's (LON:VRP) chief medical officer Kathy Rickard. Rickard recaps on the recent positive top-line Phase 2b results the firm reported for its COPD drug ensifentrine and discusses why she believes it has the potential to change patients' lives.
She says they're now looking forward to their planned meeting with the U.S. FDA which is due to take place in the second quarter.
0 Comments